報告題目: Finding Novel Anti-Tuberculosis Compounds

主講人: Prof. Joo-Won Suh （徐胄源教授）

主講人簡介：

 徐胄源博士1990年到至今為韓國明知大學生命科學情報系教授，2011到至今為韓國21世紀綠色生物食醫藥素材開發事業項目團團長，曾任韓國微生物與生物技術學會副主席👋🏻，韓國應用生物化學學會主席🐤，主要研究方向為微生物來源活性天然產物發現及生物合成🦄，主持承擔多項韓國政府資助的研究項目🏯，以及多項企業合作研發項目。

報告時間: 6月19日 (星期二) 下午2:00-3:30

報告地點👋🏻：上海交大EON体育4平台3-405

聯系人: 趙心清 xqzhao@sjtu.edu.cn

Abstract:

Tuberculosis (TB) has been known to be an infectious disease caused by Mycobacterium tuberculosis (M. tb) and the MDR (multidrug resistant) and XDR (extensively drug re-sistant) TB incidence currently continue to increase globally. Therefore, the development of new anti-tuberculosis drugs is required for effective treatment of MDR and XDR TB.

In order to address this issue, we screened over 150,000 actinomycetes extracts through in vitro assay using M. tb resistant to existed drugs and isolated two anti-tuberculosis lead compounds as named to Ecumicin and rufomycin. Through DARTS (Drug Affinity Responsive Target Stability) and mutation analysis, we discovered the mode of action that ecumicin and rufomycin, and developed the ClpC1 based screening assay for de-velopment of the ClpC1 inhibitor as anti-tuberculosis lead compounds since M. tb ClpC1 is a druggable target for development of novel anti-tuberculosis lead compounds. This assay has so far been in agreement with payed contraction to GATB (Global Alliance for TB drug development), which is non-profit institute of top-level in TB research support-ed by Bill and Melinda Gates Foundation. Furthermore, we are focusing to produce var-ious cyclic peptides by Split-Intein, which target the ClpC1 specifically. In conclusion, these strategies regarding cyclic peptides targeting M. tb ClpC1 will pave the way for the development of novel anti-tuberculosis lead compounds and eventually save lives from MDR and XDR TB.